Market news

This stock is worth loading up on whenever it's on the cheap side.

The company has a history of developing treatments that have achieved widespread adoption.

Participants who took the experimental drug retatrutide experienced the largest weight loss ever seen in a drug trial for diabetes.

Two new studies on the experimental drug retatrutide show it helps overweight people lose weight, whether or not they have diabetes.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

Zepbound 15 mg was associated with 4.5 percentage points more weight loss than Wegovy HD.

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.

Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study

Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo Nordisk's semaglutide treatments.

Eli Lilly launches a global commitment to close the diabetes and obesity treatment gap in low-income countries by 2040.

Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.

Eli Lilly says Foundayo beat oral semaglutide in weight loss and A1C for type 2 diabetes in new analysis.

Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm’s current obesity focus. The Breakthrough Therapy status for...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 17.2% on an annualized basis producing an average annual return of 30.75%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.

Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]

Eli Lilly CEO David Ricks eyes larger biopharma deals in infectious disease, women’s, and mental health, targeting earlier stage assets. Read more here.

Ricks told Bloomberg that the world’s largest drugmaker will keep spending the cash from its weight-loss and diabetes franchise to buy its next act, not just defend the current one.

Novo Nordisk (NYSE:NVO) finally has a CagriSema result it can put next to Eli Lilly’s (NYSE:LLY) tirzepatide and come out ahead. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes taking the 1 mg/ 1 mg dose of CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with […]

FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly and Company (NYSE: LLY) is launching today the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated with Lilly's innovative diabetes and obesity medicines. This means treating as many people with diabetes and obesity in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries before 2040. Today, for every 4 people in high-income countries who have access to Lilly's diabetes a

Something new is happening in the weight loss drug market.

Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.

On September 25, Eli Lilly and Company (NYSE:LLY) announced that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata (AA). The decision expands Olumiant’s label beyond established adult indications in moderately to severely active rheumatoid arthritis and severe AA, enlarging its addressable […]

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Eli Lilly and Company (NYSE:LLY) CEO David Ricks said that about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July, with roughly 70% using Lilly medicines. The temporary Medicare “Bridge” program allows eligible beneficiaries to obtain obesity treatments for a $50 monthly co-pay, giving Zepbound and Foundayo access to […]

Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks told CNBC that Foundayo now accounts for roughly one-third of new patients starting an oral GLP-1, with Lilly’s share of the pill market increasing week over week. The update comes as Lilly broke ground on a $6.5 billion manufacturing facility in Houston that is expected to be […]

Key TakeawaysEli Lilly stock has climbed 31% over the past six months, though shares sit only ~7% above their 2026 starting level as of September 23. Q2 revenue jumped 48% YoY, and management raised full-year revenue guidance to $85B-$87B.

The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in on record highs.

Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the pharma stock. But perhaps the more important change was in Foundayo estimates. Guggenheim sharply raised its revenue forecasts for Lilly’s oral obesity drug, […]

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.